N

NeuroSense Therapeutics Ltd
D

NRSN

1.31000
USD
0.01
(0.77%)
Market Closed
Volume
503
EPS
0
Div Yield
0
P/E
-1
Market Cap
25,507,018
News

Title: NeuroSense Therapeutics Ltd

Sector: Healthcare
Industry: Biotechnology
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.